Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

How much weight loss, trial by trial.

Each card is one trial arm against its own placebo, at the weeks the source reports. The default card is the highest stated milligram dose.

11 cards with an ITT estimand. 22 cards have a weight figure and no stated estimand.

Retatrutide 3

Retatrutide

4 mg · ITT

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20048121620243648607284Placebo, week 80, -3.9%Placeboretatrutide 4 mg, week 80, -17.6%retatrutide 4 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-17.6% at week 80

TRIUMPH-1 · NCT05929066

Retatrutide

9 mg · ITT

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20-25048121620243648607284Placebo, week 80, -3.9%Placeboretatrutide 9 mg, week 80, -23.7%retatrutide 9 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-23.7% at week 80

TRIUMPH-1 · NCT05929066

Retatrutide

12 mg · ITT

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20-25048121620243648607284Placebo, week 80, -3.9%Placeboretatrutide 12 mg, week 80, -25%retatrutide 12 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-25% at week 80

TRIUMPH-1 · NCT05929066

Semaglutide 3

Semaglutide

2.4 mg · ITT

Obesity or overweight

Y axis: Change in body weight from baseline, %

0-5-10-150481216202436486072Placebo, week 68, -2.4%PlaceboSemaglutide s.c. 2.4 mg once weekly, week 68, -14.9%Semaglutide s.c. 2.4 mg once weekly

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-14.9% at week 68

STEP 1 · NCT03548935

Semaglutide

7.2 mg · ITT

Obesity or overweight

Y axis: Change in body weight from baseline, %

0-5-10-15-200481216202436486072Placebo, week 72, -3.9%PlaceboSemaglutide 7.2 mg, week 72, -18.8%Semaglutide 7.2 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-18.8% at week 72

STEP UP · NCT05646706

Semaglutide

2.4 mg · ITT

Obesity or overweight

Y axis: Change in body weight from baseline, %

0-5-10-15-200481216202436486072Placebo, week 72, -3.9%PlaceboSemaglutide 2.4 mg, week 72, -15.5%Semaglutide 2.4 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-15.5% at week 72

STEP UP · NCT05646706

Survodutide 2

Survodutide

3.6 mg · ITT

Obesity + T2D

Y axis: Change in body weight from baseline, %

0-5-10-15048121620243648607284Placebo, week 76, -5.4%PlaceboSurvodutide 3.6 mg, week 76, -12.2%Survodutide 3.6 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-12.2% at week 76

SYNCHRONIZE-1 · NCT06066515

Survodutide

6.0 mg · ITT

Obesity + T2D

Y axis: Change in body weight from baseline, %

0-5-10-15048121620243648607284Placebo, week 76, -5.4%PlaceboSurvodutide 6.0 mg, week 76, -13%Survodutide 6.0 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-13% at week 76

SYNCHRONIZE-1 · NCT06066515

Tirzepatide 3

Tirzepatide

5 mg · ITT

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-150481216202436486072Placebo, week 72, -3.1%Placebo5 mg Tirzepatide, week 72, -15%5 mg Tirzepatide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-15% at week 72

SURMOUNT-1 · NCT04184622

Tirzepatide

10 mg · ITT

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-200481216202436486072Placebo, week 72, -3.1%Placebo10 mg Tirzepatide, week 72, -19.5%10 mg Tirzepatide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-19.5% at week 72

SURMOUNT-1 · NCT04184622

Tirzepatide

15 mg · ITT

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20-250481216202436486072Placebo, week 72, -3.1%Placebo15 mg Tirzepatide, week 72, -20.9%15 mg Tirzepatide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-20.9% at week 72

SURMOUNT-1 · NCT04184622

Estimand not reported 22

These arms report a weight change and do not name ITT or efficacy. They stay out of both estimand sets.

Cagrilintide/semaglutide

cagrilintide 2.4 mg and semaglutide 2.4 mg · n/r

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20-250481216202436486072Placebo, week 68, -3%PlaceboCagrisema, week 68, -20.4%Cagrisema

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-20.4% at week 68

REDEFINE 1 · NCT05567796

VK2735

2.5 mg · n/r

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-1004812162024Placebo, week 13, -1.7%PlaceboVK2735 2.5 mg, week 13, -9.1%VK2735 2.5 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-9.1% at week 13

VENTURE · NCT06068946

VK2735

15 mg · n/r

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-1504812162024Placebo, week 13, -1.7%PlaceboVK2735 15 mg, week 13, -14.7%VK2735 15 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-14.7% at week 13

VENTURE · NCT06068946

Exenatide

Dose n/r · n/r

Obesity or overweight

Y axis: Change in body weight from baseline, %

500481216202436Placebo, week 36, 3.5%PlaceboExenatide once weekly extended-release, week 36, 1.7%Exenatide once weekly extended-release

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

1.7% at week 36

ECHO · NCT02664441

Liraglutide

3.0mg · n/r

Obesity or overweight

Y axis: Change in body weight from baseline, %

5004812162024364860Placebo, week 56, 0.28%PlaceboLiraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68), week 56, 0.69%Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

0.69% at week 56

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes · NCT01272219

Liraglutide

3.0mg · n/r

Obesity or overweight

Y axis: Change in body weight from baseline, %

5004812162024364860Placebo, week 56, 0.28%PlaceboLiraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), week 56, 2.91%Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

2.91% at week 56

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes · NCT01272219

Liraglutide

Dose n/r · n/r

Obesity + T2D

Y axis: Change in body weight from baseline, %

10500481216202436Placebo, week 32, 1.4%PlaceboLiraglutide Pen Injector (Saxenda), week 32, 5.7%Liraglutide Pen Injector (Saxenda)

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

5.7% at week 32

SAXAPCOS · NCT03480022

Setmelanotide

Dose n/r · n/r

Bardet Biedl Syndrome (BBS); Alström Syndrome...

Y axis: Change in body weight from baseline, %

0-5-1004812162024364860Pivotal Cohort, week 52, -5.21%Pivotal Cohort

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-5.21% at week 52

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity · NCT03746522

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.